NO328096B1 - Medisinske aerosolformuleringer samt ny anvendelse av kromoglysinsyre og/eller nedokromil - Google Patents

Medisinske aerosolformuleringer samt ny anvendelse av kromoglysinsyre og/eller nedokromil Download PDF

Info

Publication number: NO328096B1
Authority: NO; Norway
Prior art keywords: aerosol formulation; formulation according; nedocromil; active compound; weight
Prior art date: 1998-08-04

Application number

NO20010531A

Other languages

English (en)

Norwegian (no)

Other versions

NO20010531D0 (no

NO20010531L (no

Inventor

Kurt Herzog

Manfred Keller

Rudi Mueller-Walz

Holger Kraus

Original Assignee

Jagotec Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-04

Filing date

2001-01-31

Publication date

2009-12-07

2001-01-31 Application filed by Jagotec Ag filed Critical Jagotec Ag

2001-01-31 Publication of NO20010531D0 publication Critical patent/NO20010531D0/no

2001-01-31 Publication of NO20010531L publication Critical patent/NO20010531L/no

2009-12-07 Publication of NO328096B1 publication Critical patent/NO328096B1/no

Links

239000000203 mixture Substances 0.000 title claims abstract description 85
239000000443 aerosol Substances 0.000 title claims abstract description 66
238000009472 formulation Methods 0.000 title claims abstract description 59
239000002253 acid Substances 0.000 title claims abstract description 36
150000001875 compounds Chemical class 0.000 claims abstract description 80
RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 claims abstract description 35
239000000725 suspension Substances 0.000 claims abstract description 35
150000003839 salts Chemical class 0.000 claims abstract description 30
229960004398 nedocromil Drugs 0.000 claims abstract description 21
239000004094 surface-active agent Substances 0.000 claims abstract description 14
239000007787 solid Substances 0.000 claims abstract description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 63
239000003380 propellant Substances 0.000 claims description 48
GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 claims description 36
YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims description 28
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 24
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 claims description 24
229960000265 cromoglicic acid Drugs 0.000 claims description 23
239000002245 particle Substances 0.000 claims description 23
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 21
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims description 19
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 18
239000001272 nitrous oxide Substances 0.000 claims description 17
239000007921 spray Substances 0.000 claims description 16
239000001569 carbon dioxide Substances 0.000 claims description 12
229910002092 carbon dioxide Inorganic materials 0.000 claims description 12
150000005828 hydrofluoroalkanes Chemical class 0.000 claims description 11
229960002462 glycopyrronium bromide Drugs 0.000 claims description 10
-1 alkali metal salt Chemical class 0.000 claims description 9
PDNHLCRMUIGNBV-UHFFFAOYSA-N 1-pyridin-2-ylethanamine Chemical compound CC(N)C1=CC=CC=N1 PDNHLCRMUIGNBV-UHFFFAOYSA-N 0.000 claims description 8
229960002259 nedocromil sodium Drugs 0.000 claims description 8
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 7
239000002904 solvent Substances 0.000 claims description 7
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 6
229960004436 budesonide Drugs 0.000 claims description 6
239000003245 coal Substances 0.000 claims description 6
229960002714 fluticasone Drugs 0.000 claims description 6
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 6
239000007788 liquid Substances 0.000 claims description 6
NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 claims description 4
LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims description 4
ANGKOCUUWGHLCE-HKUYNNGSSA-N [(3s)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1[N+](C)(C)CC[C@@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-HKUYNNGSSA-N 0.000 claims description 4
229960003728 ciclesonide Drugs 0.000 claims description 4
BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 4
229960002848 formoterol Drugs 0.000 claims description 4
229960001888 ipratropium Drugs 0.000 claims description 4
OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 claims description 4
229950008204 levosalbutamol Drugs 0.000 claims description 4
229960001664 mometasone Drugs 0.000 claims description 4
QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims description 4
IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 claims description 4
229950004432 rofleponide Drugs 0.000 claims description 4
229960004017 salmeterol Drugs 0.000 claims description 4
LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims description 4
229940110309 tiotropium Drugs 0.000 claims description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 3
229940092705 beclomethasone Drugs 0.000 claims description 3
231100000252 nontoxic Toxicity 0.000 claims description 3
230000003000 nontoxic effect Effects 0.000 claims description 3
229960000797 oxitropium Drugs 0.000 claims description 3
NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 claims description 3
229910052708 sodium Inorganic materials 0.000 claims description 3
239000011734 sodium Substances 0.000 claims description 3
LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 claims description 2
229910052783 alkali metal Inorganic materials 0.000 claims description 2
229910052784 alkaline earth metal Inorganic materials 0.000 claims description 2
XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 claims description 2
229960002576 amiloride Drugs 0.000 claims description 2
230000003110 anti-inflammatory effect Effects 0.000 claims description 2
229960001117 clenbuterol Drugs 0.000 claims description 2
STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 claims description 2
229960001022 fenoterol Drugs 0.000 claims description 2
229960000676 flunisolide Drugs 0.000 claims description 2
229960001798 loteprednol Drugs 0.000 claims description 2
YPZVAYHNBBHPTO-MXRBDKCISA-N loteprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)OCCl)[C@@H]4[C@@H]3CCC2=C1 YPZVAYHNBBHPTO-MXRBDKCISA-N 0.000 claims description 2
MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims description 2
230000035945 sensitivity Effects 0.000 claims description 2
230000003266 anti-allergic effect Effects 0.000 claims 1
230000001078 anti-cholinergic effect Effects 0.000 claims 1
230000003278 mimic effect Effects 0.000 claims 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 1
239000000126 substance Substances 0.000 abstract description 9
239000000969 carrier Substances 0.000 abstract description 7
238000000034 method Methods 0.000 description 18
229960001730 nitrous oxide Drugs 0.000 description 17
229910052782 aluminium Inorganic materials 0.000 description 14
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 14
238000011049 filling Methods 0.000 description 14
239000000654 additive Substances 0.000 description 13
230000000996 additive effect Effects 0.000 description 13
238000000265 homogenisation Methods 0.000 description 13
OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 description 9
229960000193 formoterol fumarate Drugs 0.000 description 9
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 8
NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 8
238000003756 stirring Methods 0.000 description 8
230000000694 effects Effects 0.000 description 7
230000009467 reduction Effects 0.000 description 7
ANGKOCUUWGHLCE-UHFFFAOYSA-N 2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester Chemical compound C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-UHFFFAOYSA-N 0.000 description 6
150000001335 aliphatic alkanes Chemical class 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
239000006185 dispersion Substances 0.000 description 6
239000000843 powder Substances 0.000 description 6
239000010419 fine particle Substances 0.000 description 5
OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 5
238000003860 storage Methods 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 4
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 4
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
239000005642 Oleic acid Substances 0.000 description 4
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 4
239000004147 Sorbitan trioleate Substances 0.000 description 4
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 4
229910052799 carbon Inorganic materials 0.000 description 4
238000009826 distribution Methods 0.000 description 4
239000001282 iso-butane Substances 0.000 description 4
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 4
235000010445 lecithin Nutrition 0.000 description 4
239000000787 lecithin Substances 0.000 description 4
229940067606 lecithin Drugs 0.000 description 4
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 4
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
229960002969 oleic acid Drugs 0.000 description 4
235000021313 oleic acid Nutrition 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
239000001294 propane Substances 0.000 description 4
235000019337 sorbitan trioleate Nutrition 0.000 description 4
229960000391 sorbitan trioleate Drugs 0.000 description 4
238000001179 sorption measurement Methods 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
KYNQOULUPYDEMV-ITSONIETSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;n-[2-hydroxy-5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 KYNQOULUPYDEMV-ITSONIETSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
239000001273 butane Substances 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
239000012876 carrier material Substances 0.000 description 3
239000006184 cosolvent Substances 0.000 description 3
230000008021 deposition Effects 0.000 description 3
239000007789 gas Substances 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
GTLACDSXYULKMZ-UHFFFAOYSA-N pentafluoroethane Chemical compound FC(F)C(F)(F)F GTLACDSXYULKMZ-UHFFFAOYSA-N 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
229960005018 salmeterol xinafoate Drugs 0.000 description 3
159000000000 sodium salts Chemical class 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 2
JQZFYIGAYWLRCC-UHFFFAOYSA-N 1-chloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)C(F)(F)Cl JQZFYIGAYWLRCC-UHFFFAOYSA-N 0.000 description 2
AWRLZJJDHWCYKN-UHFFFAOYSA-N 5-bromo-2-ethoxy-3-nitropyridine Chemical compound CCOC1=NC=C(Br)C=C1[N+]([O-])=O AWRLZJJDHWCYKN-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 2
239000004338 Dichlorodifluoromethane Substances 0.000 description 2
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
125000000129 anionic group Chemical group 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
229960000686 benzalkonium chloride Drugs 0.000 description 2
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
229920001400 block copolymer Polymers 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003246 corticosteroid Substances 0.000 description 2
229960001334 corticosteroids Drugs 0.000 description 2
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 2
235000019404 dichlorodifluoromethane Nutrition 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
229960001037 fenoterol hydrobromide Drugs 0.000 description 2
239000008103 glucose Substances 0.000 description 2
229960001031 glucose Drugs 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
229960001361 ipratropium bromide Drugs 0.000 description 2
KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 2
239000008101 lactose Substances 0.000 description 2
229960001375 lactose Drugs 0.000 description 2
239000000463 material Substances 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
229920001451 polypropylene glycol Polymers 0.000 description 2
230000008569 process Effects 0.000 description 2
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 2
229960000257 tiotropium bromide Drugs 0.000 description 2
238000009736 wetting Methods 0.000 description 2
WXGNWUVNYMJENI-UHFFFAOYSA-N 1,1,2,2-tetrafluoroethane Chemical compound FC(F)C(F)F WXGNWUVNYMJENI-UHFFFAOYSA-N 0.000 description 1
AJDIZQLSFPQPEY-UHFFFAOYSA-N 1,1,2-Trichlorotrifluoroethane Chemical compound FC(F)(Cl)C(F)(Cl)Cl AJDIZQLSFPQPEY-UHFFFAOYSA-N 0.000 description 1
WGZYQOSEVSXDNI-UHFFFAOYSA-N 1,1,2-trifluoroethane Chemical compound FCC(F)F WGZYQOSEVSXDNI-UHFFFAOYSA-N 0.000 description 1
FRCHKSNAZZFGCA-UHFFFAOYSA-N 1,1-dichloro-1-fluoroethane Chemical compound CC(F)(Cl)Cl FRCHKSNAZZFGCA-UHFFFAOYSA-N 0.000 description 1
NPNPZTNLOVBDOC-UHFFFAOYSA-N 1,1-difluoroethane Chemical compound CC(F)F NPNPZTNLOVBDOC-UHFFFAOYSA-N 0.000 description 1
229940051271 1,1-difluoroethane Drugs 0.000 description 1
YMRMDGSNYHCUCL-UHFFFAOYSA-N 1,2-dichloro-1,1,2-trifluoroethane Chemical compound FC(Cl)C(F)(F)Cl YMRMDGSNYHCUCL-UHFFFAOYSA-N 0.000 description 1
SKDFWEPBABSFMG-UHFFFAOYSA-N 1,2-dichloro-1,1-difluoroethane Chemical compound FC(F)(Cl)CCl SKDFWEPBABSFMG-UHFFFAOYSA-N 0.000 description 1
RFCAUADVODFSLZ-UHFFFAOYSA-N 1-Chloro-1,1,2,2,2-pentafluoroethane Chemical compound FC(F)(F)C(F)(F)Cl RFCAUADVODFSLZ-UHFFFAOYSA-N 0.000 description 1
BOUGCJDAQLKBQH-UHFFFAOYSA-N 1-chloro-1,2,2,2-tetrafluoroethane Chemical compound FC(Cl)C(F)(F)F BOUGCJDAQLKBQH-UHFFFAOYSA-N 0.000 description 1
FWAQVJAOVDYHAF-UHFFFAOYSA-N 1-chloro-1,2,2-trifluoroethane Chemical compound FC(F)C(F)Cl FWAQVJAOVDYHAF-UHFFFAOYSA-N 0.000 description 1
OHMHBGPWCHTMQE-UHFFFAOYSA-N 2,2-dichloro-1,1,1-trifluoroethane Chemical compound FC(F)(F)C(Cl)Cl OHMHBGPWCHTMQE-UHFFFAOYSA-N 0.000 description 1
CYXIKYKBLDZZNW-UHFFFAOYSA-N 2-Chloro-1,1,1-trifluoroethane Chemical compound FC(F)(F)CCl CYXIKYKBLDZZNW-UHFFFAOYSA-N 0.000 description 1
BNPSSFBOAGDEEL-NMFAMCKASA-N 4-[(1r)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;sulfuric acid Chemical compound OS(O)(=O)=O.CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-NMFAMCKASA-N 0.000 description 1
XSFWDHONRBZVEJ-UHFFFAOYSA-N 7-[3-[[2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]amino]propyl]-1,3-dimethylpurine-2,6-dione;hydron;chloride Chemical compound Cl.C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 XSFWDHONRBZVEJ-UHFFFAOYSA-N 0.000 description 1
NVOYVOBDTVTBDX-AGUVMIOSSA-N 8g15t83e6i Chemical compound C1([C@@H](CO)C(=O)OC2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CC)=CC=CC=C1 NVOYVOBDTVTBDX-AGUVMIOSSA-N 0.000 description 1
108090000312 Calcium Channels Proteins 0.000 description 1
102000003922 Calcium Channels Human genes 0.000 description 1
UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 1
XWCDCDSDNJVCLO-UHFFFAOYSA-N Chlorofluoromethane Chemical compound FCCl XWCDCDSDNJVCLO-UHFFFAOYSA-N 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
229960004308 acetylcysteine Drugs 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000013566 allergen Substances 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229940125388 beta agonist Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
229960001927 cetylpyridinium chloride Drugs 0.000 description 1
YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000019406 chloropentafluoroethane Nutrition 0.000 description 1
AFYPFACVUDMOHA-UHFFFAOYSA-N chlorotrifluoromethane Chemical compound FC(F)(F)Cl AFYPFACVUDMOHA-UHFFFAOYSA-N 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
OPXKTCUYRHXSBK-UHFFFAOYSA-N clenbuterol hydrochloride Chemical compound Cl.CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 OPXKTCUYRHXSBK-UHFFFAOYSA-N 0.000 description 1
229960001399 clenbuterol hydrochloride Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000004939 coking Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
239000004062 cytokinin Substances 0.000 description 1
150000001983 dialkylethers Chemical class 0.000 description 1
UMNKXPULIDJLSU-UHFFFAOYSA-N dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 description 1
229940099364 dichlorofluoromethane Drugs 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
238000005188 flotation Methods 0.000 description 1
WEGNFRKBIKYVLC-XTLNBZDDSA-N flunisolide acetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WEGNFRKBIKYVLC-XTLNBZDDSA-N 0.000 description 1
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
229960000289 fluticasone propionate Drugs 0.000 description 1
WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
239000000446 fuel Substances 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
239000011521 glass Substances 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
238000000227 grinding Methods 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
229940125389 long-acting beta agonist Drugs 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229960002744 mometasone furoate Drugs 0.000 description 1
WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
JQEKDNLKIVGXAU-UHFFFAOYSA-L nedocromil sodium Chemical compound [Na+].[Na+].CCN1C(C([O-])=O)=CC(=O)C2=C1C(CCC)=C1OC(C([O-])=O)=CC(=O)C1=C2 JQEKDNLKIVGXAU-UHFFFAOYSA-L 0.000 description 1
235000013842 nitrous oxide Nutrition 0.000 description 1
QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
210000003300 oropharynx Anatomy 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229960001609 oxitropium bromide Drugs 0.000 description 1
LCELQERNWLBPSY-KHSTUMNDSA-M oxitropium bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CC)=CC=CC=C1 LCELQERNWLBPSY-KHSTUMNDSA-M 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
229960004065 perflutren Drugs 0.000 description 1
239000012071 phase Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000007639 printing Methods 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
229960000261 reproterol hydrochloride Drugs 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
238000011076 safety test Methods 0.000 description 1
238000007789 sealing Methods 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Dispersion Chemistry (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pulmonology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Otolaryngology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)

NO20010531A 1998-08-04 2001-01-31 Medisinske aerosolformuleringer samt ny anvendelse av kromoglysinsyre og/eller nedokromil NO328096B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CH163398		1998-08-04
PCT/CH1999/000360 WO2000007567A1 (fr)	1998-08-04	1999-08-02	Formulations d'aerosol a usage medical

Publications (3)

Publication Number	Publication Date
NO20010531D0 NO20010531D0 (no)	2001-01-31
NO20010531L NO20010531L (no)	2001-01-31
NO328096B1 true NO328096B1 (no)	2009-12-07

Family

ID=4215022

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20010531A NO328096B1 (no)	1998-08-04	2001-01-31	Medisinske aerosolformuleringer samt ny anvendelse av kromoglysinsyre og/eller nedokromil
NO2012019C NO2012019I2 (no)	1998-08-04	2012-12-10	Kombinasjon av flutikason og formoterol, eller hvilket som helst farmasøytisk akseptabelt salt ellerderivat derav som er beskyttet ved basispatentet, inkludert kombinasjonen av flutikasonpropionat og formoterolfumarat

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO2012019C NO2012019I2 (no)	1998-08-04	2012-12-10	Kombinasjon av flutikason og formoterol, eller hvilket som helst farmasøytisk akseptabelt salt ellerderivat derav som er beskyttet ved basispatentet, inkludert kombinasjonen av flutikasonpropionat og formoterolfumarat

Country Status (19)

Country	Link
US (1)	US6475467B1 (fr)
EP (1)	EP1102579B1 (fr)
JP (1)	JP4672143B2 (fr)
CN (1)	CN1150890C (fr)
AT (1)	ATE234604T1 (fr)
AU (1)	AU749697B2 (fr)
BE (1)	BE2013C027I2 (fr)
CA (1)	CA2338680C (fr)
CY (1)	CY2012033I2 (fr)
DE (1)	DE59904648D1 (fr)
DK (1)	DK1102579T3 (fr)
ES (1)	ES2193726T3 (fr)
FR (1)	FR13C0057I2 (fr)
LU (1)	LU92254I2 (fr)
NO (2)	NO328096B1 (fr)
NZ (1)	NZ509489A (fr)
PT (1)	PT1102579E (fr)
WO (1)	WO2000007567A1 (fr)
ZA (1)	ZA200100569B (fr)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AUPN814496A0 (en) *	1996-02-19	1996-03-14	Monash University	Dermal penetration enhancer
GB9616237D0 (en)	1996-08-01	1996-09-11	Norton Healthcare Ltd	Aerosol formulations
US20010031244A1 (en)	1997-06-13	2001-10-18	Chiesi Farmaceutici S.P.A.	Pharmaceutical aerosol composition
DZ2947A1 (fr)	1998-11-25	2004-03-15	Chiesi Farma Spa	Inhalateur à compteur de dose sous pression.
GB9902689D0 (en) *	1999-02-08	1999-03-31	Novartis Ag	Organic compounds
DE19921693A1 (de) *	1999-05-12	2000-11-16	Boehringer Ingelheim Pharma	Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US20100197719A1 (en) *	1999-05-12	2010-08-05	Boehringer Ingelheim Pharma Kg	Medicament compositions containing anticholinergically-effective compounds and betamimetics
US7214687B2 (en)	1999-07-14	2007-05-08	Almirall Ag	Quinuclidine derivatives and medicinal compositions containing the same
ES2165768B1 (es)	1999-07-14	2003-04-01	Almirall Prodesfarma Sa	Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
IT1313553B1 (it)	1999-07-23	2002-09-09	Chiesi Farma Spa	Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
PE20010720A1 (es) *	1999-12-11	2001-07-26	Glaxo Group Ltd	Distribuidor de medicamento
US6651655B1 (en) *	2000-01-18	2003-11-25	Quadrant Technologies Limited	Inhaled vaccines
IT1317846B1 (it)	2000-02-22	2003-07-15	Chiesi Farma Spa	Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0008660D0 (en) *	2000-04-07	2000-05-31	Arakis Ltd	The treatment of respiratory diseases
US20060257324A1 (en) *	2000-05-22	2006-11-16	Chiesi Farmaceutici S.P.A.	Pharmaceutical solution formulations for pressurised metered dose inhalers
EE05167B1 (et)	2000-05-22	2009-06-15	Chiesi Farmaceutici S.P.A.	Stabiilsed farmatseutilised lahuspreparaadid survestatud doseerivatele inhalaatoritele
FR2812545B1 (fr) *	2000-08-03	2003-03-28	Air Liquide Sante Int	Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur
US20040081627A1 (en) *	2000-10-09	2004-04-29	Jinks Phillip A	Medicinal aerosol formulations
US6908928B2 (en)	2000-10-12	2005-06-21	Bi Pharma Kg.	Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
CN100519558C (zh) *	2000-10-12	2009-07-29	贝林格尔英格海姆法玛两合公司	结晶单水合物、其制备方法及其在制备药物组合中的用途
US7776315B2 (en) *	2000-10-31	2010-08-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pharmaceutical compositions based on anticholinergics and additional active ingredients
EE05343B1 (et) *	2000-10-31	2010-10-15	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Tiotroopiumsoola sisaldav inhaleeritav lahusekompositsioon
US20020137764A1 (en)	2000-10-31	2002-09-26	Karin Drechsel	Inhalable formulation of a solution containing a tiotropium salt
US6620438B2 (en) *	2001-03-08	2003-09-16	Boehringer Ingelheim Pharma Kg	Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
US20100310477A1 (en) *	2000-11-28	2010-12-09	Boehringer Ingelheim Pharma Gmbh & Co. Kg.	Pharmaceutical compositions based on anticholingerics and additional active ingredients
DE10111843A1 (de) *	2001-03-13	2002-09-19	Boehringer Ingelheim Pharma	Verbindungen zur Behandlung von inflammatorischen Erkrankungen
EP1372608B1 (fr) *	2001-03-30	2007-10-10	Jagotec Ag	Formulations aerosol medicales
US20030055026A1 (en)	2001-04-17	2003-03-20	Dey L.P.	Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en)	2001-04-17	2003-12-23	Dey, L.P.	Bronchodilating compositions and methods
US20030013675A1 (en) *	2001-05-25	2003-01-16	Boehringer Ingelheim Pharma Kg	Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
US6472563B1 (en) *	2001-11-09	2002-10-29	Sepracor Inc.	Formoterol tartrate process and polymorph
US6858615B2 (en)	2002-02-19	2005-02-22	Parion Sciences, Inc.	Phenyl guanidine sodium channel blockers
DK3384931T3 (da) *	2002-03-01	2019-09-16	Chiesi Farm Spa	Superfin formoterolformulering
DE10212264A1 (de)	2002-03-20	2003-10-02	Boehringer Ingelheim Pharma	Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
DE10214263A1 (de) *	2002-03-28	2003-10-16	Boehringer Ingelheim Pharma	HFA-Suspensionsformulierungen enthaltend ein Anticholinergikum
US7244415B2 (en) *	2002-03-28	2007-07-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	HFA suspension formulations of an anhydrate
US7311894B2 (en) *	2002-03-28	2007-12-25	Boehringer Ingelheim Pharma Gmbh & Co. Kg	HFA suspension formulations containing an anticholinergic
DE10214264A1 (de) *	2002-03-28	2003-10-16	Boehringer Ingelheim Pharma	HFA-Suspensionsformulierungen eines Anhydrats
GB0207899D0 (en) *	2002-04-05	2002-05-15	3M Innovative Properties Co	Formoterol and cielesonide aerosol formulations
GB0207906D0 (en) *	2002-04-05	2002-05-15	3M Innovative Properties Co	Formoterol and mometasone aerosol formulations
US20050186141A1 (en) *	2002-06-25	2005-08-25	Acrux Dds Pty Ltd.	Transdermal aerosol compositions
KR20100055542A (ko)	2002-06-25	2010-05-26	애크럭스 디디에스 피티와이 리미티드	비정질 약학적 조성물을 이용한 경피전달속도의 제어
US20050181032A1 (en) *	2002-06-25	2005-08-18	Acrux Dds Pty Ltd.	Metastable pharmaceutical compositions
KR20100080865A (ko) *	2002-12-10	2010-07-12	세프라코 아이엔시.	레발부테롤 염
HRP20050611B1 (hr) *	2002-12-12	2013-12-20	Takeda Gmbh	Kombinacijski lijek
US20050058606A1 (en) *	2002-12-16	2005-03-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Tiotropium containing HFC solution formulations
US20040152720A1 (en) *	2002-12-20	2004-08-05	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Powdered medicaments containing a tiotropium salt and salmeterol xinafoate
CN1292748C (zh) *	2003-03-05	2007-01-03	南昌弘益科技有限公司	噻托溴铵吸入粉雾剂及其制备工艺
KR101113003B1 (ko) *	2003-03-20	2012-02-24	베링거 인겔하임 파마슈티칼즈, 인코포레이티드	추진제로 하이드로-플루오로-알칸을 사용하는 계량 흡입기용 제형
US20060293293A1 (en) *	2003-05-22	2006-12-28	Altana Pharma Ag	Salmeterol and ciclesonide combination
GB0312148D0 (en)	2003-05-28	2003-07-02	Aventis Pharma Ltd	Stabilized pharmaceutical products
WO2004110460A1 (fr)	2003-06-13	2004-12-23	Altana Pharma Ag	Combinaison de formoterol et de ciclesonide
GB0315889D0 (en) *	2003-07-08	2003-08-13	Aventis Pharma Ltd	Stable pharmaceutical products
TWI359675B (en)	2003-07-10	2012-03-11	Dey L P	Bronchodilating β-agonist compositions
US20050026948A1 (en) *	2003-07-29	2005-02-03	Boehringer Ingelheim International Gmbh	Medicaments for inhalation comprising an anticholinergic and a betamimetic
DK1658063T3 (da) *	2003-08-06	2014-05-12	Galephar M F	Fordelagtige kombinationer til inhalering af nacystelyn og bronkodilatorer
US7745442B2 (en)	2003-08-20	2010-06-29	Parion Sciences, Inc.	Methods of reducing risk of infection from pathogens
EP1670482B2 (fr) *	2003-09-16	2022-06-29	Covis Pharma B.V.	Utilisation de ciclesonide dans le traitement de maladies respiratoires
CA2576410A1 (fr) *	2003-09-18	2006-03-31	Norton Healthcare Ltd.	Particules
GB0323684D0 (en) *	2003-10-09	2003-11-12	Jagotec Ag	Improvements in or relating to organic compounds
GB0323685D0 (en) *	2003-10-09	2003-11-12	Jagotec Ag	Improvements in or relating to organic compounds
CA2550841C (fr) *	2004-02-06	2012-10-02	Meda Pharma Gmbh & Co. Kg	Nouvelle combinaison d'anticholinergique et de beta-mimetiques pour le traitement de maladies respiratoires
HRP20120286T1 (hr) *	2004-02-06	2012-04-30	Meda Pharma Gmbh & Co. Kg	Kombinacija antikolinergika i inhibitora fosfodiesteraze tip 4 za liječenje respiratornih bolesti
PL1713473T3 (pl) *	2004-02-06	2013-08-30	Meda Pharma Gmbh & Co Kg	Kombinacja leków antycholinergicznych i glikokortykoidów do długotrwałego leczenia astmy i POChP
JP2007524698A (ja) *	2004-02-27	2007-08-30	アルタナ　ファルマ　アクチエンゲゼルシャフト	シクレソニドとグリコピロニウムとの組合せ物
EP1595531A1 (fr)	2004-05-13	2005-11-16	CHIESI FARMACEUTICI S.p.A.	Formulation d'une solution pharmaceutique stable pour aérosols doseurs sous pression
US20070134165A1 (en) *	2004-04-20	2007-06-14	Altana Pharma Ag	Use of Ciclesonide for the Treatment of Respiratory Disease in a Smoking Patient
MXPA06012240A (es)	2004-04-23	2007-01-31	Cydex Inc	Formulacion para inhalador de polvo seco que contiene eter sulfoalquilico-ciclodextrina.
AU2013201437B2 (en) *	2004-04-23	2015-09-03	Cydex Pharmaceuticals, Inc	DPI formulation containing sulfoalkyl ether cyclodextrin
US20050238632A1 (en) *	2004-04-23	2005-10-27	Alburty David S	Propellant formulations
ITRM20040268A1 (it) *	2004-05-31	2004-08-31	Italchimici S P A	Formulazione farmaceutica di una soluzione stabile di formoterolo per via inalatoria e suo precedimento di preparazione.
ES2257152B1 (es) *	2004-05-31	2007-07-01	Laboratorios Almirall S.A.	Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
EP1809243B2 (fr) *	2004-07-02	2022-06-08	Boehringer Ingelheim International GmbH	Formulations de suspensions aerosol contenant tg 227 ea en tant qu'agent propulseur
JP3955868B2 (ja) *	2004-12-27	2007-08-08	株式会社キングジム	書類等の綴じ具
BRPI0519481A2 (pt)	2004-12-27	2009-02-03	Beiersdorf Ag	glicopirrolato em preparaÇÕes cosmÉticas
DE102005029390A1 (de) *	2005-06-23	2007-01-04	Beiersdorf Ag	Wirkstoffkombinationen aus Glycopyrroniumbromid und Polyolen
GB0501956D0 (en) *	2005-01-31	2005-03-09	Arrow Internat	Nebulizer formulation
JP4991693B2 (ja) *	2005-03-16	2012-08-01	メダファーマゲゼルシャフトミットベシュレンクテルハフツングウントコンパニーコマンディトゲゼルシャフト	呼吸器疾患の治療のための抗コリン作用薬及びロイコトリエン受容体アンタゴニストの組み合わせ剤
US20060239935A1 (en) *	2005-04-23	2006-10-26	Boehringer Ingelheim International Gmbh	Compositions for inhalation
EP1879571A1 (fr) *	2005-04-23	2008-01-23	Boehringer Ingelheim International GmbH	Combinaison de medicaments a inhaler contenant un betamimetique et un steroide en plus d'un anticholinergique
DK1881980T3 (da)	2005-05-02	2012-10-01	Boehringer Ingelheim Int	Nye krystalline former af tiotropiumbromid
NZ563946A (en) *	2005-06-03	2012-02-24	Acrux Dds Pty Ltd	Testosterone containing non-occlusive transdermal drug delivery composition for application to the arm pit / axilla
US7629331B2 (en)	2005-10-26	2009-12-08	Cydex Pharmaceuticals, Inc.	Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
AU2012200449B2 (en) *	2005-12-21	2013-07-25	Meda Pharma Gmbh & Co Kg	Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE4 inhibitor and antileukotriene for the treatment of inflammatory diseases
NZ568349A (en)	2005-12-21	2011-05-27	Meda Pharma Gmbh & Co Kg	Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
DE102006017320A1 (de) *	2006-04-11	2007-10-18	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
ES2298049B1 (es) *	2006-07-21	2009-10-20	Laboratorios Almirall S.A.	Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
EP2101767A2 (fr) *	2006-12-07	2009-09-23	Eli Lilly & Company	Article de fabrication pour le prasugrel
DE102007002121B4 (de) *	2007-01-10	2008-12-11	Dräger, Karl-Heinz	Verwendung eines Flüssiggasgemisches als nichtbrennbares Treibgas zum Feinstverteilen eines Reiz- oder Kampfstoffes
CA2608561A1 (fr) *	2007-10-29	2009-04-29	Carl Paluszkiewicz	Support d'accessoires de deflecteur pour motocyclette
EP2100599A1 (fr)	2008-03-13	2009-09-16	Laboratorios Almirall, S.A.	Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP2100598A1 (fr) *	2008-03-13	2009-09-16	Laboratorios Almirall, S.A.	Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques
EP3111926B1 (fr)	2009-05-29	2019-12-11	Pearl Therapeutics, Inc.	Compositions, procédés et systèmes pour une administration respiratoire de deux ou de plusieurs agents actifs
US8815258B2 (en)	2009-05-29	2014-08-26	Pearl Therapeutics, Inc.	Compositions, methods and systems for respiratory delivery of two or more active agents
TR200907237A2 (tr) *	2009-09-23	2011-04-21	B�Lg�� Mahmut	Tiotropyum kuru toz kombinasyonu
GB0918149D0 (en) *	2009-10-16	2009-12-02	Jagotec Ag	Improved medicinal aerosol formulation
TR200907914A2 (tr)	2009-10-20	2011-05-23	B�Lg�� Mahmut	Kortlkosteroid içeren kuru toz formunda farmasötik bileşim.
AR079451A1 (es)	2009-12-18	2012-01-25	Nycomed Gmbh	Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina
BR112012015334A2 (pt) *	2009-12-23	2016-03-15	Chiesi Farma Spa	terapia combinada para doença pulmonar obstrutiva crônica
UA106098C2 (uk)	2009-12-23	2014-07-25	К'Єзі Фармачеутічі С.П.А.	Аерозольна композиція для хозл
CA2785321C (fr) *	2009-12-23	2018-08-21	Chiesi Farmaceutici S.P.A.	Polytherapie pour bronchopneumopathie chronique obstructive (copd)
TR200909793A2 (tr)	2009-12-25	2011-07-21	B�Lg�� Mahmut	Tiotropyum, mometazon ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu.
TR200909789A2 (tr)	2009-12-25	2011-07-21	B�Lg�� Mahmut	Tiotropyum, budesonid ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu
US8834931B2 (en)	2009-12-25	2014-09-16	Mahmut Bilgic	Dry powder formulation containing tiotropium for inhalation
TR200909791A2 (tr) *	2009-12-25	2011-07-21	B�Lg�� Mahmut	Salmeterol ve flutikazon içeren farmasötik bileşim@
TR200909790A2 (tr) *	2009-12-25	2011-07-21	Bi̇lgi̇ç Mahmut	Tiotropyum, formoterol ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu.
TR200909792A2 (tr)	2009-12-25	2011-07-21	B�Lg�� Mahmut	Tiotropyum, kortikosteroid ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu
EP2510928A1 (fr)	2011-04-15	2012-10-17	Almirall, S.A.	Aclidinium pour l'amélioration du sommeil des patients avec des maldadies respiratoires
GB201108039D0 (en)	2011-05-13	2011-06-29	Mexichem Amanco Holding Sa	Compositions
JP2014519519A (ja)	2011-06-15	2014-08-14	タケダゲゼルシャフトミットベシュレンクテルハフツング	新規３，４，４ａ，１０ｂ−テトラヒドロ−１Ｈ−チオピラノ［４，３−ｃ］イソキノリン化合物
JP5980318B2 (ja)	2011-06-17	2016-08-31	タケダゲー・エム・ベー・ハーＴａｋｅｄａＧｍｂＨ	新規のフタラジノン−ピロロピリミジンカルボキサミド誘導体
AR086745A1 (es)	2011-06-27	2014-01-22	Parion Sciences Inc	3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
GB201117621D0 (en)	2011-10-12	2011-11-23	Mexichem Amanco Holding Sa	Compositions
GB201117619D0 (en)	2011-10-12	2011-11-23	Mexichem Amanco Holding Sa	Compositions
BR112015014178A2 (pt)	2012-12-17	2017-07-11	Parion Sciences Inc	compostos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil)carbamimidoil) pirazina-2- carboxamida
HUE032891T2 (hu)	2012-12-17	2017-11-28	Parion Sciences Inc	Klórpirazin-karboxamid-származékok nem kielégítõ nyálkahártya-hidratáció által elõsegített megbetegedések kezelésére
WO2014113638A1 (fr) *	2013-01-17	2014-07-24	Aer Devices, Inc.	Formulations d'albutérol pour thérapie d'entretien à usages multiples et dispositifs s'y rapportant
RU2696582C2 (ru)	2013-03-15	2019-08-05	Перл Терапьютикс, Инк.	Способы и системы кондиционирования дисперсных кристаллических материалов
GB201306984D0 (en)	2013-04-17	2013-05-29	Mexichem Amanco Holding Sa	Composition
US9102633B2 (en)	2013-12-13	2015-08-11	Parion Sciences, Inc.	Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
HUE039513T2 (hu)	2013-12-30	2019-01-28	Chiesi Farm Spa	Glikopirrónium-bromid és formoterol kombinációját tartalmazó nyomás alatti stabil aeroszol oldatkészítmény
US20160367520A1 (en) *	2014-02-10	2016-12-22	Patara Pharma, LLC	Mast cell stabilizers for lung disease treatment
DK3104853T3 (da)	2014-02-10	2019-12-09	Respivant Sciences Gmbh	Behandling med mastcellestabilisatorer til systemiske forstyrrelser
WO2017027402A1 (fr)	2015-08-07	2017-02-16	Patara Pharma, LLC	Méthodes de traitement de troubles systémiques aptes à être traités par des stabilisateurs de mastocytes, y compris de troubles liés aux mastocytes
US10238625B2 (en)	2015-08-07	2019-03-26	Respivant Sciences Gmbh	Methods for the treatment of mast cell related disorders with mast cell stabilizers
WO2017093758A1 (fr)	2015-12-04	2017-06-08	Mexichem Fluor S.A. De C.V.	Composition pharmaceutique
AU2017321495A1 (en)	2016-08-31	2019-03-21	Respivant Sciences Gmbh	Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
ES2957459T3 (es) *	2016-09-19	2024-01-19	Mexichem Fluor Sa De Cv	Composición farmacéutica que comprende glicopirrolato
MX384545B (es)	2016-09-19	2025-03-14	Mexichem Fluor Sa De Cv	Composicion farmaceutica
CA3037080C (fr)	2016-09-19	2021-05-18	Mexichem Fluor S.A. De C.V.	Compositions pharmaceutiques stables comprenant de l'indacaterol et du 1,1-difluoroethane (hfa 152a) pour utilisation dans des aerosols-doseurs
EP3522983A4 (fr)	2016-10-07	2020-06-03	Respivant Sciences GmbH	Compositions à base de cromolyne pour le traitement d'une fibrose pulmonaire
WO2018069210A1 (fr)	2016-10-10	2018-04-19	Takeda Gmbh	Tétrahydrofuro [3,4-c] isoquinolines en tant qu'inhibiteurs de pde4
US10555903B2 (en) *	2016-10-14	2020-02-11	Glenmark Specialty S.A.	Nebulizable compositions of tiotropium and formoterol
UA122811C2 (uk) *	2018-08-10	2021-01-06	Наталія Миколаївна Тихонівська	Фармацевтична композиція
PE20221439A1 (es)	2019-12-02	2022-09-21	Chiesi Farm Spa	Lata de acero inoxidable para inhaladores dosificadores presurizados
CN112972384B (zh) *	2019-12-02	2022-03-18	长风药业股份有限公司	一种格隆溴铵和茚达特罗原料药微粉混合物的制备方法
JP2023519199A (ja) *	2020-03-25	2023-05-10	インスメッドインコーポレイテッド	トレプロスチニルプロドラッグの医薬製剤及びその使用方法
WO2023227781A1 (fr) *	2022-05-27	2023-11-30	Chiesi Farmaceutici S.P.A.	Formulation pharmaceutique pour aérosol-doseur sous pression
WO2023227782A1 (fr) *	2022-05-27	2023-11-30	Chiesi Farmaceutici S.P.A.	Formulation pharmaceutique pour aérosol-doseur pressurisé
WO2023227783A1 (fr) *	2022-05-27	2023-11-30	Chiesi Farmaceutici S.P.A.	Formulation pharmaceutique pour aérosol-doseur sous pression

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE555319A (fr)	1956-03-21	1900-01-01
BE556587A (fr)	1957-01-31	1957-04-11
US4405598A (en) *	1976-01-30	1983-09-20	Fisons, Limited	Composition for treating asthma
FI770215A7 (fr)	1976-01-30	1977-07-31	Fisons Ltd
NL7708731A (nl)	1976-08-13	1978-02-15	Montedison Spa	Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen.
CA1075854A (fr)	1976-08-16	1980-04-22	Charles W. Simons	Agents propulseurs aerosol pour produits a usage personnel
FR2390951A1 (fr)	1977-05-17	1978-12-15	Oreal	Nouvelles compositions cosmetiques sous forme de laques aerosols pour fixer la chevelure
CY1333A (en) *	1980-04-30	1986-10-24	Fisons Ltd	Pharmaceutical compositions containing cromoglycates
JPS61158919A (ja)	1984-12-28	1986-07-18	Taisho Pharmaceut Co Ltd	水虫治療剤
GB8820398D0 (en) *	1988-08-27	1988-09-28	Fisons Plc	Pharmaceutical formulation
IE62780B1 (en) *	1988-09-10	1995-02-22	Fisons Plc	Inhalation devices with a reduced risk of blockage
DE3839258A1 (de) *	1988-11-21	1990-05-23	Norbert Sass	Verfahren zur herstellung eines suspensions-aerosols
US5225183A (en)	1988-12-06	1993-07-06	Riker Laboratories, Inc.	Medicinal aerosol formulations
GB8828477D0 (en)	1988-12-06	1989-01-05	Riker Laboratories Inc	Medical aerosol formulations
GB8921222D0 (en) *	1989-09-20	1989-11-08	Riker Laboratories Inc	Medicinal aerosol formulations
DE4003272A1 (de) *	1990-02-03	1991-08-08	Boehringer Ingelheim Kg	Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
ATE147973T1 (de)	1990-06-29	1997-02-15	Fisons Plc	Druckaerosolzusammensetzung
US5753208A (en) *	1990-11-09	1998-05-19	Egis Gyogyszergyar	Antiasthmatic aerosol preparation of sodium cromoglycate
HU205249B (en) *	1990-11-09	1992-04-28	Egyt Gyogyszervegyeszeti Gyar	Process for producing suspensive aerosole composition
EP0504112A3 (en)	1991-03-14	1993-04-21	Ciba-Geigy Ag	Pharmaceutical aerosol formulations
PT1086688E (pt) *	1991-12-18	2004-06-30	Minnesota Mining & Mfg	Formulacoes de aerossol em suspensao
DE59206234D1 (de)	1991-12-31	1996-06-13	Hoechst Ag	Medizinische Aerosolformulierung
SE523661C2 (sv)	1992-02-05	2004-05-04	American Pacific Corp	Gas-vätskeblandning avsedd för användning som brandsläckningsmedel
US5301664A (en)	1992-03-06	1994-04-12	Sievers Robert E	Methods and apparatus for drug delivery using supercritical solutions
GB9214765D0 (en)	1992-07-11	1992-08-26	Smithkline Beecham Plc	Pressurised aerosol formulation
WO1994003056A1 (fr)	1992-07-31	1994-02-17	Ian Alexander Edwin Maccormick	Composition insecticide en aerosol
FI972655L (fi)	1994-12-22	1997-06-19	Astra Ab	Aerosolilääkeformuloinnit
GEP20002254B (en) *	1995-04-14	2000-10-25	Glaxo Wellcome Inc	Metered Dose Inhaler, the Inhaler System Comprising the Same and Method for Treatment of Respiratory Disturbances
DE19616573C2 (de) *	1996-04-25	1999-03-04	Pari Gmbh	Verwendung unterkritischer Treibmittelmischungen und Aerosole für die Mikronisierung von Arzneimitteln mit Hilfe dichter Gase
FR2764899B1 (fr)	1997-06-19	2001-04-06	Boehringer Ingelheim Alimentai	Nouveau melange propulseur et les preparations alimentaires en aerosol le contenant

1999
- 1999-08-02 CA CA002338680A patent/CA2338680C/fr not_active Expired - Lifetime
- 1999-08-02 EP EP99932599A patent/EP1102579B1/fr not_active Expired - Lifetime
- 1999-08-02 NZ NZ509489A patent/NZ509489A/xx not_active IP Right Cessation
- 1999-08-02 US US09/744,798 patent/US6475467B1/en not_active Expired - Lifetime
- 1999-08-02 DE DE59904648T patent/DE59904648D1/de not_active Expired - Lifetime
- 1999-08-02 PT PT99932599T patent/PT1102579E/pt unknown
- 1999-08-02 DK DK99932599T patent/DK1102579T3/da active
- 1999-08-02 ES ES99932599T patent/ES2193726T3/es not_active Expired - Lifetime
- 1999-08-02 CN CNB998104361A patent/CN1150890C/zh not_active Expired - Lifetime
- 1999-08-02 JP JP2000563253A patent/JP4672143B2/ja not_active Expired - Lifetime
- 1999-08-02 AT AT99932599T patent/ATE234604T1/de active
- 1999-08-02 WO PCT/CH1999/000360 patent/WO2000007567A1/fr not_active Ceased
- 1999-08-02 AU AU48939/99A patent/AU749697B2/en not_active Expired
2001
- 2001-01-19 ZA ZA200100569A patent/ZA200100569B/xx unknown
- 2001-01-31 NO NO20010531A patent/NO328096B1/no not_active IP Right Cessation
2012
- 2012-11-30 CY CY2012033C patent/CY2012033I2/el unknown
- 2012-12-10 NO NO2012019C patent/NO2012019I2/no unknown
2013
- 2013-05-06 BE BE2013C027C patent/BE2013C027I2/fr unknown
- 2013-07-17 LU LU92254C patent/LU92254I2/fr unknown
- 2013-10-15 FR FR13C0057C patent/FR13C0057I2/fr active Active

Also Published As

Publication number	Publication date
PT1102579E (pt)	2003-07-31
CA2338680A1 (fr)	2000-02-17
NZ509489A (en)	2002-10-25
JP2002522374A (ja)	2002-07-23
CN1315852A (zh)	2001-10-03
NO20010531D0 (no)	2001-01-31
AU4893999A (en)	2000-02-28
LU92254I2 (fr)	2013-09-17
CY2012033I1 (el)	2015-08-05
CA2338680C (fr)	2008-10-14
EP1102579B1 (fr)	2003-03-19
CY2012033I2 (el)	2015-08-05
AU749697B2 (en)	2002-07-04
FR13C0057I1 (fr)	2013-11-15
JP4672143B2 (ja)	2011-04-20
US6475467B1 (en)	2002-11-05
CN1150890C (zh)	2004-05-26
NO2012019I2 (no)	2014-06-02
WO2000007567A1 (fr)	2000-02-17
DK1102579T3 (da)	2003-07-14
FR13C0057I2 (fr)	2020-04-03
EP1102579A1 (fr)	2001-05-30
ATE234604T1 (de)	2003-04-15
NO2012019I1 (no)	2012-12-27
BE2013C027I2 (fr)	2018-12-04
ES2193726T3 (es)	2003-11-01
ZA200100569B (en)	2001-09-26
DE59904648D1 (de)	2003-04-24
NO20010531L (no)	2001-01-31

Legal Events

Date

Code

Title

Description

2012-12-27

SPCF

Filing of supplementary protection certificate

Free format text: PRODUCT NAME: FLUTIFORM / IFFERA (ALTERNATIVE NAVN FOR SAMME PRODUKT); NAT. REG. NO/DATE: 10-7474-10-7476 20120827; FIRST REG. NO/DATE: 21395-21397 20120710

Spc suppl protection certif: 2012019

Filing date: 20121210

2014-06-23

SPCG

Granted supplementary protection certificate